Summary of the technology
Novel Bile Acid Conjugates for the Treatment of NAFLD/NASH and Obesity
Project ID : 7-2011-2563
Description of the technology
- Fatty liver disease - Non alcoholic fatty liver disease (NAFLD) isa continuum of diseases that include simple steatosis and non-alcoholic steatohepatitis (NASH) ultimately leading to cirrhosis, hepatocellular carcinoma (HCC) and/or end stage liver failure which develop in the absence of excessive alcohol intake.
- NAFLD affects 30% of the general population and 70-80% of diabetic and obesity patients. Simple steatosis is most often considered to have a benign hepatic pathological prognosis. NASH, as oppose to steatosis is pathologically characterized by the presence of steatosis and inflammation, and is related to higher morbidity and mortality.
- NASH is accounted for liver related complications, and it is one of the leading causes of liver transplantation.
- A novel bile acid related small molecule that can be used to treat NAFLD and NASH. We have synthesized an Arginine-bile acid conjugate (CDCArg) that was tested in animal nutritional models of NAFLD and obesity.
- The compound is highly effective in preventing nutritional-induced NASH/NAFLD.
- The compound is highly effective in treating nutrition-induced NASH/NAFLD.
- The compound was effective in lowering body weight of obese high-fat diet fed mice.
- A novel, orally administered, treatment for NAFLD and obesity.
- Mechanism of action elucidated;Non-toxic.
- Significantly lowering lipids absorption with no effect on protein absorption.